About me
Irfan Qureshi, M.D., Chief Medical Officer, Biohaven (NYSE: BHVN) is a Board-certified neurologist with more than 20 years of experience in industry, academia, and patient care.
Biohaven is a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments in key therapeutic areas including neuroscience, immunology and oncology. The company is known for transforming the migraine treatment paradigm with rimegepant — the first all-in-one migraine medication for the acute and preventive treatment of migraine. Under Dr. Qureshi’s leadership, Biohaven is now advancing one of the industry's most innovative therapeutic portfolios which includes Kv7 ion channel modulation for epilepsy and mood disorders; extracellular protein degradation for inflammatory and immunological diseases; TRPM3 ion channel antagonism for migraine and pain; TYK2/JAK1 inhibition for neuroinflammatory and neurodegenerative disorders; glutamate modulation for spinocerebellar ataxia and obsessive-compulsive disorder; myostatin inhibition for neuromuscular and metabolic diseases, including obesity; and antibody recruiting, bispecific molecules and antibody drug conjugates for cancer.
Prior to joining Biohaven, Dr. Qureshi held positions at Bristol-Myers Squibb and the Albert Einstein College of Medicine, where he continues to serve as Clinical Assistant Professor in the Department of Neurology. He completed neurology training and earned his M.D. from Einstein and graduated with Honors from Johns Hopkins University with a B.S. in Biomedical Engineering.
